New hope for transfusion-dependent anemia patients: drug aims to cut blood needs

NCT ID NCT05891249

Ongoing Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 22 times

Summary

This study tests the safety and effectiveness of luspatercept in 85 adults with anemia due to myelodysplastic syndromes (MDS) or beta-thalassemia who need regular red blood cell transfusions. The goal is to see if the drug can reduce the number of transfusions needed. Participants must have had a poor response to or be unable to use standard erythropoietin therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Local Institution - 0001

New Delhi, National Capital Territory of Delhi, 110029, India
Local Institution - 0002

Ahmedabad, Gujarat, 380009, India
Local Institution - 0003

Bangalore, 560027, India
Local Institution - 0004

Chandigarh, 160012, India
Local Institution - 0005

Assam, 781032, India
Local Institution - 0006

Hyderabad, 500034, India
Local Institution - 0007

Kolkata, West Bengal, 700014, India
Local Institution - 0008

Mumbai, 400012, India
Local Institution - 0010

Delhi, 110085, India

Conditions

Explore the condition pages connected to this study.

ANEMIA